HISUN(SH:600267)2019-04-22 16:00Financial Performance - Net profit attributable to shareholders of the listed company was ¥31,731,435.96, representing a significant increase of 194.06% year-on-year[12]. - Operating revenue for the period was ¥2,797,540,454.36, showing a decrease of 0.86% compared to the same period last year[12]. - Basic earnings per share increased by 200% to ¥0.033 from ¥0.011 in the same period last year[12]. - The company's net profit attributable to shareholders increased by 194.06% to RMB 31,731,435.96 compared to the same period last year, primarily due to increased gross profit from product sales[25]. - The company reported a net profit excluding non-recurring gains and losses of ¥25,424,105.20, compared to a loss of ¥6,896,455.42 in the previous year[12]. - Net profit for Q1 2019 was CNY 155,145,162.40, an increase of 19.19% compared to CNY 130,201,771.18 in Q1 2018[53]. - The net profit attributable to the parent company was ¥32,606,499.67, compared to ¥13,288,872.56 in the same period last year, indicating a significant increase of 145.5%[55]. - The total comprehensive income for Q1 2019 was ¥156,020,226.11, compared to ¥132,699,889.96 in Q1 2018, marking an increase of approximately 17.6%[55]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥21,865,686,561.25, a slight increase of 0.06% compared to the end of the previous year[12]. - Current assets totaled RMB 6,007,708,776.80, a decrease of 1.31% from RMB 6,087,791,068.33 as of December 31, 2018[36]. - Non-current assets totaled RMB 15,857,977,784.45, an increase of 0.58% from RMB 15,765,855,412.62[39]. - Total liabilities decreased to RMB 14,331,048,199.36 from RMB 14,475,028,345.16, a reduction of 0.99%[40]. - Current liabilities increased to RMB 9,628,163,997.25, up from RMB 9,556,936,366.20, reflecting a rise of 0.75%[40]. - Total equity stood at ¥7,378,618,135.79, with equity attributable to shareholders of ¥6,183,496,941.69[76]. - The company’s total liabilities to equity ratio is approximately 1.96, indicating a leveraged position[74]. Cash Flow - Net cash flow from operating activities was ¥98,619,183.86, down 65.45% from ¥285,464,905.20 in the previous year[12]. - The net cash flow from operating activities for Q1 2019 was ¥98,619,183.86, a decrease from ¥285,464,905.20 in Q1 2018, representing a decline of approximately 65.5%[62]. - Cash inflow from operating activities totaled ¥2,451,194,361.82 in Q1 2019, down from ¥2,668,540,330.90 in Q1 2018, a decrease of approximately 8.1%[62]. - Total cash inflow from financing activities in Q1 2019 was CNY 2,066,676,049.78, compared to CNY 1,509,137,216.92 in Q1 2018, marking an increase of 37%[64]. - Net cash flow from financing activities for Q1 2019 was -CNY 28,656,415.34, an improvement from -CNY 331,137,823.40 in Q1 2018[64]. Shareholder Information - The total number of shareholders at the end of the reporting period was 34,805[18]. - Zhejiang Haizheng Group Co., Ltd. held 33.22% of the shares, making it the largest shareholder[18]. Investments and Subsidiaries - A new wholly-owned subsidiary for nasal spray products was established with a registered capital of RMB 50 million, with registration completed as of the report date[26]. - The company completed a capital increase of RMB 30 million for its wholly-owned subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., raising its registered capital to RMB 160 million[30]. - A joint venture for inhalation drugs was established with a registered capital of RMB 20 million, where the company holds a 49% stake[30]. - The company plans to establish a new biopharmaceutical company with a registered capital of RMB 500 million, in which it will hold 59.66% of the shares[31]. Research and Development - Research and development expenses for Q1 2019 amounted to CNY 88,846,467.86, slightly up from CNY 86,972,415.18 in Q1 2018[50]. - Research and development expenses for Q1 2019 were ¥43,350,487.63, slightly higher than ¥42,120,299.63 in Q1 2018, showing a year-over-year increase of 2.9%[55]. Other Financial Metrics - The company's income tax expense surged by 169.80% to RMB 57,375,092.32, reflecting increased profits from the subsidiary Hanhui Pharmaceutical[25]. - The company approved a financial assistance application of up to RMB 300 million from its controlling shareholder, Zhejiang Haizheng Group Co., Ltd., which remains unpaid as of the report date[26]. - The company has a total of ¥1,492,810,906.17 in accounts payable and notes payable[74].